Cerenome, Inc.
CNSY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.45M
Close$
$-0.95
157.2% downside
Current Fair Value
157.2% downsideOvervalued by 157.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.45 Million |
|---|---|
| Enterprise Value | $10.12 Million |
| Earnings per Share | $-7.19 |
| Beta | 1.47 |
| Outstanding Shares | 6,773,125 |
Return
| Return on Equity | -477.54% |
|---|---|
| Return on Assets | -185.94% |
| Return on Invested Capital | 366.70% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | -1.66 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -2.08 |
| Enterprise Value to EBIT | 0.51 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 26, 2026
EPS Estimate
$-1.04
Consensus analyst estimateRevenue Estimate
$750,000
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.04
Consensus analyst estimateRevenue Estimate
$750,000
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Plus Therapeutics Inc
2,018 employees
CEO: Marc Hedrick
Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...